Ra Capital Management, L.P. Acquires 479,039 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 479,039 shares of the company’s stock in a transaction on Tuesday, June 9th. The shares were purchased at an average cost of $6.91 per share, with a total value of $3,310,159.49. Following the completion of the acquisition, the director directly owned 15,683,034 shares in the company, valued at approximately $108,369,764.94. The trade was a 3.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. bought 103 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $7.00 per share, for a total transaction of $721.00.
• On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV traded up $0.58 on Thursday, reaching $8.00. The company’s stock had a trading volume of 1,059,213 shares, compared to its average volume of 488,136. Artiva Biotherapeutics, Inc. has a 1-year low of $1.47 and a 1-year high of $14.53. The firm has a market cap of $197.76 million, a PE ratio of -2.26 and a beta of 2.38. The business’s 50-day moving average price is $8.89 and its two-hundred day moving average price is $6.12.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, sell-side analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Analyst Ratings Changes

ARTV has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Wedbush raised their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $39.00.

Institutional Trading of Artiva Biotherapeutics

A number of large investors have recently bought and sold shares of ARTV. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics during the 2nd quarter worth about $79,000. Qube Research & Technologies Ltd bought a new stake in Artiva Biotherapeutics in the second quarter valued at $58,000. Jane Street Group LLC bought a new stake in Artiva Biotherapeutics in the second quarter valued at $67,000. Bridgeway Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the second quarter valued at about $53,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after purchasing an additional 117,733 shares during the period.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.